Renal Cell Carcinoma

P=N/A, N=58, Active, not recruiting, Wake Forest University Health Sciences | Recruiting --> Active, not recruiting | N=244 --> 58

Given its aggressive nature and substantial risk of recurrence and metastasis, diligent long-term follow-up is essential. For advanced or metastatic disease, targeted therapy and immunotherapy emerge as potential treatment options.

FOXO1 carries both prognostic and predictive relevance in mRCC and independently predicts greater benefit from IO+TKI therapy. Integration of FOXO1 with complementary immune gene features into an RF-based model provides a promising framework for precision immunotherapy in advanced RCC.

FKBP10 is closely linked to tumor progression and treatment response by contributing to metabolic reprogramming, immunosuppressive microenvironment modulation, and programmed cell death regulation, supporting its potential as a biomarker and therapeutic target for predicting prognosis, treatment response, and immunotherapy outcomes.

By integrating findings from animal models and human epidemiological studies, we further link these molecular perturbations to adverse outcomes such as dyslipidemia, impaired glucose homeostasis, immune dysfunction, and renal carcinogenesis, emphasizing inter-organ crosstalk mediated by metabolic and hormonal networks. Finally, we highlight current knowledge gaps and propose that integrating multi-omics approaches, receptor-specific models, and standardized exposure assessment frameworks will strengthen causal inference and support more predictive risk assessment strategies for PFAS-related health effects.

CALYPSO (NCT02819596) was a prospective, multi-arm trial that evaluated durvalumab alone or in combination with tremelimumab or savolitinib in metastatic ccRCC and pRCC. Also, an increase in KIM-1 during therapy was linked to worse progression-free survival (HR 1.7; 95% CI, 1.13-2.58; p = 0.01) and OS (HR 1.95; 95% CI, 1.23-3.08; p = 0.004) in ccRCC. This exploratory analysis supports the utility of KIM-1 in advanced ccRCC and pRCC.

P1, N=55, Recruiting, DeuterOncology | N=25 --> 55 | Trial completion date: Dec 2026 --> Sep 2028 | Trial primary completion date: Dec 2025 --> Sep 2027 | Active, not recruiting --> Recruiting

P=N/A, N=2000, Recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Jan 2026 --> Jan 2027

P1, N=30, Suspended, City of Hope Medical Center | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026

P2, N=350, Active, not recruiting, Actuate Therapeutics Inc. | Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2025 --> Jun 2026

We highlight that molecular analysis, particularly agnostic WGS, has a key routine role in the care of children with renal tumours. It is likely that outcomes for these young people have been improved through more accurate diagnosis and early detection of cancer predisposition.

Importantly, treatment with Eeyarestatin I, a small-molecule ER stress agonist, restored sunitinib sensitivity in tumor cells. These findings reveal a novel PABPC1-PGK1 regulatory axis underlying sunitinib resistance and suggest a promising therapeutic strategy for overcoming drug resistance in ccRCC.